annual meeting program - American Society of Clinical Oncology

SATURDAY
Saturday, June 5, 2010
2:00 PM - 6:00 PM
POSTER DISCUSSION SESSION
Genitourinary (Nonprostate) Cancer
Display Time: 2:00 PM - 6:00 PM
Display Location: E450a
Discussion Time: 5:00 PM - 6:00 PM
Discussion Location: E Hall D2
CME credit: 1
Track(s): Genitourinary Cancer
Leonard Joseph Appleman, MD, PhD—Co-Chair
University of Pittsburgh Medical Center
George Philips, MD, MBBS, MPH—Co-Chair
University of Vermont
Discussion
5:00 PM Daniel J. George, MD (Abstracts #4520–4526)
Duke University Medical Center
Prediction and Prognosis in Renal Cell Carcinoma
Discussion
5:15 PM Ulka N. Vaishampayan, MD (Abstracts #4527–4530)
Wayne State University
Trial Design and Drug Development in Renal Cell Carcinoma
Discussion
5:25 PM Mary Gospodarowicz, MD (Abstracts #4531–4538)
Princess Margaret Hospital
Germ Cell Tumors: Is Radiation Under- or Overused?
Discussion
5:40 PM Matthew I. Milowsky, MD (Abstracts #4539–4541)
Memorial Sloan-Kettering Cancer Center
Is There a Role for Targeted Therapy in Advanced Urothelial Cancer?
Discussion
5:50 PM Seth P. Lerner, MD (Abstracts #4542–4543)
Baylor College of Medicine
New Therapies in Non-muscle-invasive Urothelial Cancer
Brd. 1 Association of germline genetic markers in IL8, HIF1A, VEGFA, and VEGFR2
with treatment response to pazopanib in renal cell carcinoma. (Abstract
#4520)
H. A. Ball, C. Xu, C. N. Sternberg, N. Bing, D. Rajagopalan, C. F. Spraggs,
V. E. Mooser, R. G. Amado, L. R. Cardon, L. Pandite
Brd. 2 Pharmacogenetic pathway analysis to identify factors for survival in
metastatic renal cell cancer patients treated with sunitinib. (Abstract #4521)
K. Eechoute, A. A. van der Veldt, H. Gelderblom, J. A. Gietema, H. Guchelaar,
N. Van Erp, E. Boven, J. B. Haanen, R. Mathijssen, J. A. Wessels
Brd. 3 Use of a multiplatform analysis of plasma cytokines and angiogenic factors
(CAFs) to identify baseline CAFs associated with pazopanib response and
tumor burden in renal cell carcinoma (RCC) patients. (Abstract #4522)
H. T. Tran, Y. Liu, Y. Lin, A. Martin, K. L. Baker, H. A. Fritsche, A. J. Zurita,
L. Pandite, J. Heymach, VEG102616 Investigators, Patients, and Team
Brd. 4 A unified prognostic model for first- and second-line targeted therapy in
metastatic renal cell carcinoma (mRCC): Results from a large international
study. (Abstract #4523)
D. Y. Heng, W. Xie, G. A. Bjarnason, U. N. Vaishampayan, F. Donskov, L. Wood,
J. J. Knox, M. Tan, B. I. Rini, T. K. Choueiri
140